Webinar: Current Trends in Companion Animal Oncology

Current Trends in Companion Animal Oncology
Dr. Chad Johannes

CLICK HERE to purchase - Cost $200

Dr. Chad M. Johannes, DVM, DACVIM (SAIM, Oncology) is an Associate Professor and Executive Director of Clinical Services within the Veterinary Health System at Colorado State University.


The Future of Veterinary Oncology: What is Financially Sustainable?
1 Hour CE
The veterinary oncology market has changed dramatically over the last two decades. Several factors have impacted the cost of delivering veterinary oncology care to dogs and cats: increasing costs/fees, corporatization of veterinary specialty medicine, more FDA approved and USDA licensed therapeutics that come with higher prices, inflation, etc. Meanwhile, veterinary medicine remains a largely self-pay industry for clients with pet insurance slow to make headway in the US market. This session will provide background to the course of the veterinary oncology market over the past 15-20 years, take a deep dive into the factors impacting the industry currently, and outline potential solutions to keep the veterinary oncology market sustainable for the future.
 
Oncology for Primary Care Practice
1 Hour CE
Cancer is a leading cause of death in dogs and cats. While exact numbers are not possible to identify, current estimates are that 1 in 4 dogs will develop cancer with numbers expanding to 50% when considering dogs over the age of 10 years. The combination of incidence rates along with client expectations for advanced diagnostic and treatment options for their pets with cancer has resulted in exceptional growth of the oncology specialty. The growth within oncology and the expanding treatment options will no doubt carry over to veterinary primary care practices. This provides an opportunity for those practitioners with a special interest and skill set to provide oncology care within their practices. This session focuses on practical treatment options that are most amenable to use in primary care practice.
 
What Your Clients Want to Know About Canine Lymphoma Treatment Options
1 Hour CE           
This session will highlight key updates and available resources regarding canine lymphoma treatments (chemotherapy, immunotherapy), outcomes and costs. These factors are all critical points clients consider as they determine the best treatment option for their pet. Particular emphasis will be placed on a practical approach to succinctly communicating relevant lymphoma information to your clients.
 
Oncology Refresher: New Therapeutics Impacting Clinical Practice
1 Hour CE
The clinical availability of advanced oncology therapeutics for dogs and cats is rapidly expanding. This session reviews the science and clinical use of several new therapeutics for common canine cancers.  Discussion will highlight the potential impact these therapies may have on your canine patients in daily practice. This session will help prepare you for the most common client questions regarding this new treatment options for pets with cancer.
 
Cats with Cancer: Diagnostic and Treatment Updates
1 Hour CE
Cancer is a leading cause of death in cats. While exact numbers regarding cancer incidence in cats are not available, some estimates show that nearly 6 million cats are diagnosed with cancer annually in the US. Given that cats are generally under-medicalized compared to dogs, they often present with more advanced clinical signs and challenging treatment considerations. This session will focus on key updates on diagnostic and treatment options available for cats with cancer. Special emphasis will be placed on options more impactful to the primary care practice setting.
 
The Importance of Appetite: The Fifth Vital Sign in the Oncology Patient
1 Hour CE
Appetite is often a key determinant in a pet owners’ perceived quality of life evaluation for their dog or cat with cancer. Lack of appetite is often the first recognizable sign by pet owners that their dog or cat is not feeling well and triggers inquiry to their veterinarian’s office. Until recently, veterinarians have struggled to have effective, reliable treatment options for dogs and cats experiencing inappetence. Recent FDA approvals of ENTYCE®/ELURA™ (capromorelin oral solution) in dogs and cats, respectively, provide new options in appetite stimulant therapy. This session will review the basic science/mechanism, available data, expected side effects and best clinical use of capromorelin in dogs and cats with cancer. Case examples will be emphasized for tips that can be readily implemented in clinical practice.